AlphAIAlphAI — Financial news for AI agents
stocktitan.netOCT 231 min read$IRMD

Third-quarter results are scheduled before markets open Oct. 30; Iradimed's call starts at 11 a.m.

Iradimed Corporation (IRMD) will release its Q3 2026 financial results on Oct. 30 before market open. A conference call is scheduled for 11 a.m. ET to discuss results. IRMD specializes in MRI-compatible medical devices, including IV infusion pumps and patient monitoring systems.

Original reporting
stocktitan.net
Published Oct 23, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 12:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$IRMD
Neutral
high confidence
Mentioned
$IRMD
Relevance
5/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$IRMDNeutralMed
01

Why it matters

The upcoming earnings release will set the tone for the company's growth trajectory and may trigger re‑rating by analysts.

02

Market read

The announcement creates a short‑term trading opportunity around the Oct 30 earnings release, with potential volatility for IRMD and related med‑tech peers.

03

What to watch

Potential regulatory updates on MRI‑compatible devices or competitive product launches could materially affect the stock beyond the earnings numbers.

Relevance 5/10Novelty 5/10Timing: pre‑market on Oct 30, 2026

Background

IRMD is a niche provider of MRI‑compatible infusion pumps and patient monitoring systems, a segment with limited competition.

Company-level read

Ticker impact

$IRMDNeutralHigh confidence
Context

IRMD announced it will release its Q3 2026 results before the market opens on Oct. 30, 2026 and host a conference call at 11 a.m. ET.

Expected impact

potential short‑term pressure as traders position ahead of the results; direction depends on guidance and earnings surprise

Evidence & confidence

Earnings releases for small‑cap biotech/medical device firms typically move the stock sharply; no guidance is provided yet, so uncertainty remains.

Market effects

Sector

May affect other MRI‑compatible device makers and small‑cap medical‑technology stocks as investors compare guidance.

Regional

Primarily U.S. market; limited broader regional effect.

Global

Low; relevance confined to niche medical‑device sector.

Counterpoint

What could challenge this read

If the market over‑reacts to the announcement, a contrarian short could be considered after the earnings release if guidance is weak.

Key entities

  • Executive
    John Glenn

    Chief Financial Officer of IRMD, quoted as the media contact.

Read at source← All news

Related articles

AUG 8
$IRMDMedAI 9/10

IRadimed (IRMD) Q2 2026 Earnings Call Transcript

IRadimed (IRMD) reported Q2 2026 revenue of $20.5 million, up 0.5% from $20.4 million a year earlier. GAAP diluted EPS was $0.41 versus $0.45, and non-GAAP EPS was $0.46. Gross margin fell to 74% from 78% due to higher manufacturing costs during the 3870 pump ramp. Q3 revenue guidance is $23.0 to $24.5 million; full-year 2026 revenue guidance is $91 to $96 million.

fool.com7 min
MAY 29
$IRMDMedAI 9/10

Iradimed Corp (IRMD): 3 Things That Stood Out From Q1 Report

Iradimed Corp (IRMD) reported Q1 2026 results on May 1. The company said revenue rose 13% year over year to $22 million and net income increased 24% to $5.8 million, or $0.45 per share. Iradimed also launched its next-generation 3870 MRI-compatible IV infusion pump in Q1, with shipments expected to begin in Q2. For Q2, it forecast revenue of $20–$21 million and GAAP EPS of $0.40–$0.44; full-year 2026 revenue of $91–$96 million and GAAP EPS of $1.90–$2.05.

finance.yahoo.com4 min
OCT 23
$OVLYMed

OAK VALLEY BANCORP REPORTS 3rd QUARTER RESULTS

Oak Valley Bancorp (OVLY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE For Immediate Release Date: October 21, 2026 Contact: Rick McCarty/Jeff Gall Phone: (209) 848-2265 www.ovcb.com OAK VALLEY BANCORP REPORTS 3rd QUARTER RESULTS OAKDALE, CA - Oak Valley Bancorp (NASDAQ: OVLY) (the "Company"), the bank holding company for

SEC EDGAR 8-K3 min
OCT 23
$VTMXMed

What Corporacion Inmobiliaria Vesta (VTMX) Said on Its Q3 Earnings Call

Corporacion Inmobiliaria Vesta (VTMX) reported Q3 revenue of $79.6M, up 9.9% YoY. The company raised its 2026 revenue growth forecast to 11.5-12.5%. Management highlighted demand from AI, electronics, and e-commerce sectors, with Mercado Libre as its largest tenant. Vesta acquired a Mexico City land parcel and plans to focus on urban infill sites. Adjusted NOI and EBITDA margins improved, and credit ratings were upgraded by S&P and Fitch.

finance.yahoo.com3 min
OCT 23
$FIXHighAI 8/10

What Comfort Systems USA (FIX) Said on Its Q3 Earnings Call

Comfort Systems USA (FIX) reported Q3 operating income up 65% to $625M, with margins improving to 16.6%. EBITDA rose 61% to $668M. The company expects 2027 gross margins to remain strong. Modular operations accounted for 17% of revenue, with plans to expand capacity. Free cash flow was $806M, and the company repurchased shares and raised its dividend. CFO Bill George will retire in 2026, succeeded by Julie Shaeff. Acquisitions are expected to add over $100M in annual revenue.

finance.yahoo.com2 min
OCT 23
$RDYMed

Dr. Reddy's Laboratories Q2 Earnings Call Highlights

Dr. Reddy's Laboratories (NYSE: RDY) expects to relaunch semaglutide in November 2026, with most supply going to Canada. Q2 North America generics revenue was $264M, down 29% YoY. The company received FDA approval for its rituximab biosimilar and launched nivolumab in India. Net cash as of Sept. 30 was INR 2,502 crore, with full-year capex expected at INR 1,600-1,700 crore.

finance.yahoo.com3 min